Skip to main content
Top
Published in: Kidney 5/2010

01-09-2010

Thrombospondin-1 in Patients with Diabetic Nephropathy

Authors: Saeed Abdelwhab, Osman Fooda, Sahar Abdelmaksoud

Published in: Kidney | Issue 5/2010

Login to get access

Abstract

Thrombospondin-1 (TSP-1), a potent antiangiogenic and proatherogenic protein, has been implicated in the development of several vascular diabetic complications. The aim of the study is to find the role of TSP-1 in diabetic nephropathy. We investigated serum TSP-1 in 30 patients with type 2 diabetes mellitus and diabetic nephropathy (group 1) with renal disease grade 1 to 3 (Kidney Disease Outcomes Quality Initiative stages of kidney disease) and 15 normal control subjects (group 2). Thorough history and clinical examination, biochemical tests including renal function tests, renal ultrasound and renal artery Doppler were done to the studied groups. In addition, carotid intima media thickness and serum TSP-1 enzyme-linked immunosorbent assay were measured. Serum TSP-1 was increased in diabetic nephropathy (193.33 ± 43.28) ng/ml compared to controls (106.27 ± 38.80) ng/ml (p < 0.001). TSP-1 correlates negatively with glomerular filtration rate (p < 0.001) and positively with resistivity index (RI) of extrarenal vessels (p < 0.001) and RI intrarenal vessels (p < 0.001). There is also positive correlation between serum TSP-1 with age (p = 0.004) and carotid intima media thickness (p = 0.004). No correlation was found with proteinuria (p = 0.37). Linear regression test in group 1 shows TSP-1 is significant independent determinant for glomerular filtration rate (p < 0.001) and carotid intima media thickness (p = 0.002). The present study suggests that TSP-1 plays an important role in development of complications in Patients with diabetic nephropathy. Serum level of TSP-1 is related to renal injury and vascular disease. Further studies may be necessary to determine casual relationship between TSP-1 and renal damage and to determine the role of targeting TSP-1 in managing these complications and preventing its progress.
Literature
1.
go back to reference Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J Am Soc Nephrol. 2004;15(1):S55–7.CrossRefPubMed Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J Am Soc Nephrol. 2004;15(1):S55–7.CrossRefPubMed
2.
go back to reference Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest. 2001;107:929–34.CrossRefPubMed Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest. 2001;107:929–34.CrossRefPubMed
3.
go back to reference Hida K, Wada J, Zhang H, et al. Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats. J Lipid Res. 2000;41:1615–22.PubMed Hida K, Wada J, Zhang H, et al. Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats. J Lipid Res. 2000;41:1615–22.PubMed
4.
go back to reference Tada H, Kuboki K, Nomura K, et al. High glucose levels enhance TGF-beta1-thrombospondin-1 pathway in cultured human mesangial cells via mechanisms dependent on glucose-induced PKC activation. J Diab Complications. 2001;15:193–7.CrossRef Tada H, Kuboki K, Nomura K, et al. High glucose levels enhance TGF-beta1-thrombospondin-1 pathway in cultured human mesangial cells via mechanisms dependent on glucose-induced PKC activation. J Diab Complications. 2001;15:193–7.CrossRef
5.
go back to reference Stenina OI, Krukovets I, et al. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation. 2003;107:3209–15.CrossRefPubMed Stenina OI, Krukovets I, et al. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation. 2003;107:3209–15.CrossRefPubMed
6.
go back to reference Daniel C, Schaub K, Amann K, Lawler J, Hugo C. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes. 2007;56:2982–9.CrossRefPubMed Daniel C, Schaub K, Amann K, Lawler J, Hugo C. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes. 2007;56:2982–9.CrossRefPubMed
7.
go back to reference Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest. 1992;90:1513–22.CrossRefPubMed Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest. 1992;90:1513–22.CrossRefPubMed
8.
go back to reference Kang DH, Joly AH, et al. Impaired angiogenesis in the remnant kidney model (I): potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001;12:1434–47.PubMed Kang DH, Joly AH, et al. Impaired angiogenesis in the remnant kidney model (I): potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001;12:1434–47.PubMed
9.
go back to reference Levey AS, Bosch JP, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.PubMed Levey AS, Bosch JP, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.PubMed
10.
go back to reference Kowagishi T, Nishizawa Y, Emoto M. Impaired retinal artery blood flow in IDDM patients before clinical manifestation of diabetic retinopathy. Diab Care. 1995;18:1544–9.CrossRef Kowagishi T, Nishizawa Y, Emoto M. Impaired retinal artery blood flow in IDDM patients before clinical manifestation of diabetic retinopathy. Diab Care. 1995;18:1544–9.CrossRef
11.
go back to reference Kanters SDJM, Algra A, van Leeuwen MS, Banga JD. Reproducibility of in vivo carotid intima-media thickness measurements. Stroke 1997;28. Kanters SDJM, Algra A, van Leeuwen MS, Banga JD. Reproducibility of in vivo carotid intima-media thickness measurements. Stroke 1997;28.
12.
go back to reference Miyajima-Uchida H, Hayashi H, et al. Production and accumulation of thrombospondin-1 in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2000;41:561–7.PubMed Miyajima-Uchida H, Hayashi H, et al. Production and accumulation of thrombospondin-1 in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2000;41:561–7.PubMed
13.
go back to reference Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diab. 2001;109(2):S424–37.CrossRef Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diab. 2001;109(2):S424–37.CrossRef
14.
15.
go back to reference Bayraktar M, Dundar S, Kirazli S. Platelet factor 4, beta-thromboglobulin and thrombospondin levels in type I diabetes mellitus patients. J Int Med Res. 1994;22:90–4.PubMed Bayraktar M, Dundar S, Kirazli S. Platelet factor 4, beta-thromboglobulin and thrombospondin levels in type I diabetes mellitus patients. J Int Med Res. 1994;22:90–4.PubMed
16.
go back to reference McGregor B, Colon S, et al. Thrombospondin in human glomerulosclerosis. A marker for inflammation and early fibrosis. Am J Pathol. 1994;144:1281–7.PubMed McGregor B, Colon S, et al. Thrombospondin in human glomerulosclerosis. A marker for inflammation and early fibrosis. Am J Pathol. 1994;144:1281–7.PubMed
17.
go back to reference Gore-Hyer E, Shegogue D, et al. TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Ren Physiol. 2002;283:F707–16. Gore-Hyer E, Shegogue D, et al. TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Ren Physiol. 2002;283:F707–16.
18.
go back to reference Holmes DI, Abdel Wahab NA, Mason RM. Identification of glucose-regulated genes in human mesangial cells by mRNA differential display. Biochem Biophys Res Commun. 1997;238:179–84.CrossRefPubMed Holmes DI, Abdel Wahab NA, Mason RM. Identification of glucose-regulated genes in human mesangial cells by mRNA differential display. Biochem Biophys Res Commun. 1997;238:179–84.CrossRefPubMed
19.
go back to reference DiPietro LA, Nissan NN, et al. Thrombospondin 1 synthesis and function in wound repair. Am J Pathol. 1996;148:1851–60.PubMed DiPietro LA, Nissan NN, et al. Thrombospondin 1 synthesis and function in wound repair. Am J Pathol. 1996;148:1851–60.PubMed
20.
go back to reference Meek RL, Cooney SK, et al. Amino acids induce indicators of response to injury in glomerular mesangial cells. Am J Physiol Ren Physiol. 2003;285:F79–86. Meek RL, Cooney SK, et al. Amino acids induce indicators of response to injury in glomerular mesangial cells. Am J Physiol Ren Physiol. 2003;285:F79–86.
21.
go back to reference Yang Y-L, Chuang L-Y, et al. Thrombospondin-1 mediates distal tubule hypertrophy induced by glycated albumin. Biochem J. 2004;379(1):89–97.CrossRefPubMed Yang Y-L, Chuang L-Y, et al. Thrombospondin-1 mediates distal tubule hypertrophy induced by glycated albumin. Biochem J. 2004;379(1):89–97.CrossRefPubMed
22.
go back to reference Hohenstein B, Daniel C, et al. Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant. 2008;23(12):3880–7.CrossRefPubMed Hohenstein B, Daniel C, et al. Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant. 2008;23(12):3880–7.CrossRefPubMed
23.
go back to reference Naito T, Masaki T, et al. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol. 2004;286:F278–87.CrossRefPubMed Naito T, Masaki T, et al. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol. 2004;286:F278–87.CrossRefPubMed
24.
go back to reference Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol. 2003;23:532–43.CrossRefPubMed Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol. 2003;23:532–43.CrossRefPubMed
25.
go back to reference Hohenstein B, Daniel C, et al. Correlation of enhanced thrombospondin-1 expression, TGF-β signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant. 2008;23:3880–7.CrossRefPubMed Hohenstein B, Daniel C, et al. Correlation of enhanced thrombospondin-1 expression, TGF-β signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant. 2008;23:3880–7.CrossRefPubMed
26.
go back to reference De Muro P, Faedda R, Fresu P. Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res. 2004;49:293–8.CrossRefPubMed De Muro P, Faedda R, Fresu P. Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res. 2004;49:293–8.CrossRefPubMed
27.
go back to reference Stouffer GA, Hu Z, Sajid M. Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation. 1998;97:907–15.PubMed Stouffer GA, Hu Z, Sajid M. Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation. 1998;97:907–15.PubMed
28.
go back to reference Boekholdt SM, Trip MD, Peters RJ. Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2002;22:e24–7.CrossRefPubMed Boekholdt SM, Trip MD, Peters RJ. Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2002;22:e24–7.CrossRefPubMed
29.
go back to reference Stenina OI, Krukovets I, et al. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation. 2003;107:3209–15.CrossRefPubMed Stenina OI, Krukovets I, et al. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation. 2003;107:3209–15.CrossRefPubMed
30.
go back to reference Jurk K, Clemetson KJ, et al. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J. 2003;17(11):1490–2.PubMed Jurk K, Clemetson KJ, et al. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J. 2003;17(11):1490–2.PubMed
31.
go back to reference Antić M, Jotić A, et al. Risk factors for the development of diabetic nephropathy. Srp Arh Celok Lek. 2009;137(1–2):18–26.CrossRefPubMed Antić M, Jotić A, et al. Risk factors for the development of diabetic nephropathy. Srp Arh Celok Lek. 2009;137(1–2):18–26.CrossRefPubMed
32.
go back to reference Isenberg JS, Ridnour LA, et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A. 2005;102(37):13141–6.CrossRefPubMed Isenberg JS, Ridnour LA, et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A. 2005;102(37):13141–6.CrossRefPubMed
33.
go back to reference Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res. 2006;71:785–93.CrossRefPubMed Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res. 2006;71:785–93.CrossRefPubMed
34.
go back to reference Bornstein PT. Thrombospondins: structure and regulation of expression. FASEB J. 1992;6(14):3290–9.PubMed Bornstein PT. Thrombospondins: structure and regulation of expression. FASEB J. 1992;6(14):3290–9.PubMed
Metadata
Title
Thrombospondin-1 in Patients with Diabetic Nephropathy
Authors
Saeed Abdelwhab
Osman Fooda
Sahar Abdelmaksoud
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Kidney / Issue 5/2010
Print ISSN: 0940-7936
Electronic ISSN: 1865-5068
DOI
https://doi.org/10.1007/s00596-010-0156-4

Other articles of this Issue 5/2010

Kidney 5/2010 Go to the issue

Literature Survey

D. Dialysis

Nephrology in Brief

Nephrology in Brief 19:5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine